Weber Christopher J, Carrillo Maria C, Jagust William, Jack Clifford R, Shaw Leslie M, Trojanowski John Q, Saykin Andrew J, Beckett Laurel A, Sur Cyrille, Rao Naren P, Mendez Patricio Chrem, Black Sandra E, Li Kuncheng, Iwatsubo Takeshi, Chang Chiung-Chih, Sosa Ana Luisa, Rowe Christopher C, Perrin Richard J, Morris John C, Healan Amanda M B, Hall Stephen E, Weiner Michael W
Alzheimer's Association Chicago Illinois USA.
School of Public Health and Helen Wills Neuroscience Institute University of California Berkeley Berkeley California USA.
Alzheimers Dement (N Y). 2021 Dec 31;7(1):e12226. doi: 10.1002/trc2.12226. eCollection 2021.
The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.
全球阿尔茨海默病神经影像倡议（WW - ADNI）是一项合作项目，旨在研究可为阿尔茨海默病治疗试验提供信息的影像和生物流体标志物。它是一个公私合作项目，涉及北美、阿根廷、澳大利亚、加拿大、中国、日本、韩国、墨西哥和中国台湾地区。2004年，ADNI研究人员启动了一项自然主义的纵向研究，该研究至今仍在全球范围内持续进行。通过几个连续阶段（ADNI - 1、ADNI - GO、ADNI - 2和ADNI - 3），该研究推动了淀粉样蛋白和tau蛋白表型分析，并完善了神经影像方法。WW - ADNI研究人员成功地实现了分析标准化，并毫无保留地公开共享数据，为其他研究人员提供了丰富的数据集。2020年8月26日，阿尔茨海默病协会召集了WW - ADNI研究人员，他们分享了ADNI - 3的最新情况以及对ADNI - 4的愿景。
